TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02860403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: motor imagery
Description: Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: motor imagery
Description: Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
Study: NCT02133079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous gp96 vaccination
Description: vaccination of autologous gp96 derived from tumor tissue + basal treatment
Study: NCT03073512

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound examination
Description: Participants will undergo ultrasound examination at 32 weeks gestation
Study: NCT01716000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal gel imaging
Description: Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vaginal gel imaging
Description: Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer aided self interview
Description: Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer aided self interview
Description: Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
Study: NCT04429763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord derived mesenchymal stem cells
Description: One dosis of 1\*10\^6 cells/Kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01979185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184SS
Study: NCT00526799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 3.5mg/m2 weekly, 3 weeks on and one week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 3.5mg/m2 weekly, 3 weeks on and one week off.
Study: NCT04002128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.
Description: Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.
Description: Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
Study: NCT05586750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: 40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
Study: NCT01682954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: 16-week nutrition, physical activity and behavioral intervention
Study: NCT00319501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular autoinjector; administered at onset of an episode

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanquix Auto-Injector (Diazepam Injection)
Description: Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
Study: NCT00740571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: strategy in which the patient starts with amitriptyline, during 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Strategy in which patient starts with pregabalin
Study: NCT03360604

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Diet
Description: This intervention is a diet consisting of a Low GI breakfast, lunch and snack meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Glycaemic Diet
Description: This intervention is a diet consisting of a High GI breakfast, lunch and snack meal.
Study: NCT04226872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Tools for Care - In Care
Description: Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting.
Study: NCT02264561

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food
Description: Active group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food
Description: Active group

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food
Description: Control group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food
Description: Control group
Study: NCT02694965

Intervention type: OTHER
Intervention: observational

Intervention type: OTHER
Intervention: observational
Study: NCT02426944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC
Description: Medical arm, patients will be treated by NOAC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Description: The patients will be treated by interventional closure of the left atrial appendage.
Study: NCT04046692

Intervention type: OTHER
Intervention: Hospital School Experience, point of view of the children
Description: Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.

Intervention type: OTHER
Intervention: Hospital School Experience, point of view of the children
Description: Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.

Intervention type: OTHER
Intervention: Hospital School Experience, point of view of the hospital teachers
Description: operators interview hospital teachers and make them complete a questionnaire (CEESQ)

Intervention type: OTHER
Intervention: Hospital School Experience, point of view of the non hospital teachers
Description: operators interview the teachers and make them complete a questionnaire (CEESQ)

Intervention type: OTHER
Intervention: Hospital School Experience, point of view of parents
Description: Operators interview parents
Study: NCT03805399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib with Capecitabine
Description: If patients were LAR subtype with HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)
Description: B1: if patients were LAR subtype without HER2 gene activated mutation, but had PI3KCA mutation, she would receive everolimus 10mg qd combined with AR inhibitor SHR3680 240mg qd continuously ; B2: if patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with CDK4/6 inhibitor SHR6390 150mg qd (three week on one week off); B4: If patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with EZH2 inhibitor SHR2554 300mg bid continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti PD-1 with nab-paclitaxel
Description: If patients were IM subtype, she will receive PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw (three week on one week off).
Study: NCT01588015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus-CMV fusion peptide vaccine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00831792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK1258
Description: 4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
Study: NCT03771027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The low FODMAP diet.
Description: The low FODMAP group had reduced the intake of FODMAP. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The diet based on NICE guidelines.
Description: The control group based on NICE guidelines received diet contained products with different FODMAP content. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
Study: NCT03046290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circumcision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circumcision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study: NCT03032796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body-Brain Trainer
Description: A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Trainer
Description: A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Trainer
Description: The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expectancy Matched Control
Description: The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
Study: NCT00514332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent
Description: stent placement for colorectal cancer obstruction
Study: NCT01700790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir and ritonavir
Description: Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
Study: NCT01724788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUROSEMIDE
Description: Pharmaceutical form: Solution Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUROSEMIDE
Description: Pharmaceutical form: Solution Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUROSEMIDE (HOE058)
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUROSEMIDE (HOE058)
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT00320489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine pamoate depot
Description: 405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
Study: NCT00697229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular injection, 1 or 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular injection, 1 or 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular injection, 1 or 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular injection, 1 or 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular injection, 1 or 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular injection, 1 or 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: Intramuscular injection, 1 or 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: Intramuscular injection, 1 or 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: Intramuscular injection, 1 or 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: Intramuscular injection, 1 or 3 doses
Study: NCT05586750

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
Study: NCT00697229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: Intramuscular injection, 1 or 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: Intramuscular injection, 1 or 3 doses
Study: NCT03805399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor included therapy
Description: If patients were BLIS subtype and had a BRCA gene pathogenic mutation, she will receive PARP inhibitor SHR3162 150mg bid and famitinib 20mg qd continuously .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLIS with anti-VEGFR included therapy
Description: If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation , she will receive:~E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off); E3: famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off); E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MES with anti-VEGFR included therapy
Description: If patients were MES subtype and without PI3K/AKT pathway activation,she will receive famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off).
Study: NCT03741270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabivax-S
Description: Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).
Study: NCT03805399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor with nab-paclitaxel
Description: If patients were MES subtype and had PI3K/AKT pathway activation, she will receive mTOR inhibitor 10mg qd continuously combined with nab-paclitaxel 100mg qw (three week on one week off).
Study: NCT00450255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study: NCT00398710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: 150 mg daily (100 mg daily in case of dose reduction)
Study: NCT04044391

Intervention type: DIAGNOSTIC_TEST
Intervention: CardioFlux Magnetocardiograph
Description: CardioFlux is a noninvasive diagnostic modality which can measure and image the heart's intrinsic magnetic field created by ion transit across cardiac cell membranes.
Study: NCT02843633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom™ Drug Coated Coronary Stent System
Description: a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Drug
Description: Dual antiplatelet therapy for one month followed by single antiplatelet therapy indefinitely. Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice
Study: NCT00450255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02552875

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tetanic stimulation
Description: 50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Staircase Stimulation
Description: TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon